Sanaria Inc.
40
1
1
32
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
5.0%
2 terminated/withdrawn out of 40 trials
94.1%
+7.6% vs industry average
0%
0 trials in Phase 3/4
25%
8 of 32 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (40)
Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria
Role: lead
Malaria CVD 36000; Gates INV090205
Role: collaborator
Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults
Role: lead
Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
Role: lead
Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults
Role: lead
Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults
Role: collaborator
A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI
Role: lead
Controlled Human Malaria Infection Transmission Model - Phase A
Role: collaborator
PfSPZ Vaccine Trial in Malian Children
Role: lead
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
Role: lead
Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children
Role: lead
Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites
Role: collaborator
Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali
Role: collaborator
Dose Escalation PfSPZ-CVac
Role: collaborator
Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge Model
Role: collaborator
Regimen Optimization Trial of PfSPZ Vaccine in Equatorial Guinea
Role: lead
Study of Safety and Effectiveness of Intravenous Immunization With PfSPZ Vaccine in Healthy African Adults
Role: collaborator
Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P Chemoprophylaxis
Role: collaborator
Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya
Role: lead
Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults
Role: lead